Dravet Syndrome Market to Exhibit Moderate Growth Rate till 2032, Investigates DelveInsight | Key Companies - Takeda, Biocodex, Zogenix, Epygenix, PTC Therapeutics, and Several Others

The Dravet Syndrome Market Insights report from DelveInsight provides a thorough understanding of current therapeutic approaches, emerging medications, Dravet Syndrome market share of particular therapies, and current and projected market sizes from 2019 to 2032, divided into the 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

Dravet Syndrome: An Overview

According to the Dravet Syndrome Foundation, Dravet syndrome (DS) is a rare, catastrophic, lifelong form of epilepsy that begins in the first year of life with frequent and/or prolonged seizures. As per NORD (National Organization for Rare Disorders), it has been defined as a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.

Download a sample copy of the market report- https://www.delveinsight.com/sample-request/b-cell-maturation-antigen-targeted-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key highlights of the Dravet Syndrome Market Report
• According to the Dravet Syndrome Foundation, Dravet syndrome is a rare, catastrophic, lifelong form of epilepsy that begins in the first year of life with frequent and/or prolonged seizures. Previously known as Severe Myoclonic Epilepsy of Infancy (SMEI), it affects 1:15,700 individuals, 80% of whom have a mutation in their SCN1A gene.
• As per DelveInsight, the total incident population of Dravet Syndrome in the seven major markets was 36,300+ in 2017.
• The United States accounted for the maximum number of Dravet Syndrome patients with 20,700+ cases in 2017 followed by Germany with 2,800+ cases.
• DelveInsight estimates suggest that missense mutation was found to have the highest number of incident cases among the Dravet Syndrome patient population in the US.

Dravet Syndrome Epidemiology
The epidemiology section covers insights about the historical and current Dravet Syndrome patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Dravet Syndrome Epidemiology Segmentation
• Incident Population of Dravet Syndrome
• Seizure associated cases of Dravet Syndrome
• Age-specific Incidence of Dravet Syndrome
• Mutations (type and class) associated with Dravet Syndrome
• Gender-specific Incidence of Dravet Syndrome

Explore more about the market report- https://www.delveinsight.com/report-store/b-cell-maturation-antigen-targeted-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dravet Syndrome Market Therapeutics

Current treatment options are limited, and the constant care required for someone suffering from Dravet syndrome can severely impact the patient's and the family's quality of life. Patients with Dravet syndrome face a 15-20% mortality rate due to SUDEP (Sudden Unexpected Death in Epilepsy), prolonged seizures, seizure-related accidents such as drowning, and infections. To provide effective therapeutics solutions, globally some of the key companies are actively working towards the development of new therapies for Dravet Syndrome. The launch of emerging therapies is expected to transform the treatment dynamics.

Dravet Syndrome Treatment Market

Current treatment options are limited, and the constant care required for someone suffering from Dravet syndrome can severely impact the patient's and the family's quality of life. Patients with Dravet syndrome face a 15-20% mortality rate due to SUDEP (Sudden Unexpected Death in Epilepsy), prolonged seizures, seizure-related accidents such as drowning, and infections.

Dravet Syndrome Market Outlook

Despite these shortcomings, in recent years Dravet syndrome has received significant attention from the pharmaceutical industry, and the pipeline has matured to include not only symptomatic but also disease-modifying treatment. At present, Pharmacological management of Dravet syndrome focuses largely on the use antiepileptic drugs such as Valproic Acid, Clobazam, Topiramate, Levetiracetam, Zonisamide and Stiripentol.
Dravet Syndrome Emerging Drugs Analysis
Companies have shifted their focus on the development of second-generation therapeutics that follow the step of the Epidiolex and the most advanced serotonergic drug (Fintepla). Most of these compounds would have the potential to treat other forms of epilepsy and are expected to hit the market during the forecasted period of (2020-2030).

Explore more about the report- https://www.delveinsight.com/report-store/b-cell-maturation-antigen-targeted-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Some of the key companies in the Dravet Syndrome Market include:
• GW Pharmaceuticals
• Ovid Therapeutics
• Takeda
• Biocodex
• Zogenix
• PTC Therapeutics
• Epygenix Therapeutics, and several others

Dravet Syndrome Therapies covered in the report include:
• Diacomit
• Epidiolex
• Ataluren
• Soticlestat (OV935/TAK-935)
• Fintepla (fenfluramine), and several others

Table of Content
1. Key Insights
2. Executive Summary
3. Dravet Syndrome Competitive Intelligence Analysis
4. Dravet Syndrome Market Overview at a Glance
5. Dravet Syndrome Disease Background and Overview
6. Dravet Syndrome Patient Journey
7. Dravet Syndrome Epidemiology and Patient Population
8. Dravet Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Dravet Syndrome Unmet Needs
10. Key Endpoints of Dravet Syndrome Treatment
11. Dravet Syndrome Marketed Products
12. Dravet Syndrome Emerging Therapies
13. Dravet Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Dravet Syndrome Market Outlook (7 major markets)
16. Dravet Syndrome Access and Reimbursement Overview
17. KOL Views on the Dravet Syndrome Market.
18. Dravet Syndrome Market Drivers
19. Dravet Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

For any query or doubt, just connect with us- https://www.delveinsight.com/sample-request/b-cell-maturation-antigen-targeted-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.